title: [Retrospective survey on the clinical features of non-Hodgkin lymphomas in Gunma Prefecture, Japan].
abstract: We retrospectively investigated pathological types, clinical backgrounds, treatments and prognoses in 726 adult patients with newly diagnosed malignant lymphoma in Gunma Prefecture. They consisted of 679 patients with non-Hodgkin lymphoma (B-cell type, 603; T- and NK-cell type, 76) of which 376 patients had diffuse large B-cell lymphoma (DLBCL) and 47 patients with Hodgkin lymphoma. When comparing the prognosis of DLBCL between patients receiving rituximab (R-CHOP group; n=212) and not using rituximab (CHOP group; n=126), both 3-year overall survival (73.5% vs 61.7%, p=0.010) and 3-year progression-free survival (65.1% vs 45.8%, p<0.001) were statistically better in the R-CHOP group compared to the CHOP group. Our results suggest that more than half of patients were DLBCL and the rituximab-containing regimen results in an improved prognosis for DLBCL patients.
authors.affiliation: Department of Medicine and Clinical Science, Graduate School of Medicine, Gunma University.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Hashimoto
authors.forename: Akihiko
authors.initials: A
authors.lastname: Yokohama
authors.forename: Akio
authors.initials: A
authors.lastname: Saitoh
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Nakahashi
authors.forename: Kohtaro
authors.initials: K
authors.lastname: Toyama
authors.forename: Takeki
authors.initials: T
authors.lastname: Mitsui
authors.forename: Hiromi
authors.initials: H
authors.lastname: Koiso
authors.forename: Takayuki
authors.initials: T
authors.lastname: Saitoh
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Handa
authors.forename: Hideki
authors.initials: H
authors.lastname: Uchiumi
authors.forename: Takahiro
authors.initials: T
authors.lastname: Jinbo
authors.forename: Kayoko
authors.initials: K
authors.lastname: Murayama
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Tamaki
authors.forename: Morio
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Morio
authors.initials: M
authors.lastname: Sawamura
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Karasawa
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Murakami
authors.forename: Junko
authors.initials: J
authors.lastname: Hirato
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Nojima
authors.forename: Masaru
authors.initials: M
authors.lastname: Kojima
authors.forename: Norifumi
authors.initials: N
authors.lastname: Tsukamoto
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D000069283:Rituximab; D015996:Survival Rate
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab